Book Cover
Home  |   Healthcare   |  Sickle Cell Disease Diagnosis Market

Sickle Cell Disease Diagnosis Market Size, Share, Growth, and Industry Analysis, By Type (Can distinguish, Cannot distinguish), By Application (Newborn, Adult), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Sickle Cell Disease Diagnosis Market Overview

The global Sickle Cell Disease Diagnosis Market is predicted to progress from USD 70.91 Million in 2026 to USD 111.13 Million by 2035, registering a CAGR of 5.12% through 2026-2035.

The Sickle Cell Disease Diagnosis Market is developing as healthcare systems strengthen early identification of inherited hemoglobin disorders, expand newborn screening, and improve access to confirmatory testing. Approximately 68% of estimated product demand is associated with tests that can distinguish sickle cell disease from carrier status, reflecting the clinical importance of identifying different hemoglobin patterns. Diagnostic laboratories increasingly combine electrophoresis, high-performance liquid chromatography, and rapid immunoassays to evaluate abnormal hemoglobin. Point-of-care testing is gaining attention in underserved communities where conventional laboratory infrastructure is limited. Increasing awareness of childhood complications, genetic counseling requirements, and timely clinical intervention supports demand. 

The United States Sickle Cell Disease Diagnosis Market benefits from universal state-level newborn screening, established clinical laboratories, and specialized hematology services. Newborn testing represents an indicative 64% of domestic application demand in this analytical framework, reflecting structured screening immediately after birth. Healthcare institutions use standardized specimen collection, laboratory hemoglobin analysis, and confirmatory diagnostic pathways to identify affected infants. Continued interest in rapid testing supports evaluation among adults requiring carrier screening, reproductive counseling, and clinical assessment. Public health surveillance and improved coordination between laboratories and treatment centers reinforce demand for accurate diagnostic technologies. 

Global Sickle Cell Disease Diagnosis Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Expanding newborn screening programs and increasing demand for early disease identification drive market growth, with sub-Saharan Africa accounting for nearly 80% of the global sickle cell disease burden.
  • Major Market Restraint: Limited diagnostic infrastructure and difficulties distinguishing sickle cell disease from carrier status restrict adoption, with Cannot distinguish tests accounting for an indicative 32% of product demand.
  • Emerging Trends: Rapid point-of-care immunoassays are improving hemoglobin variant detection and diagnostic accessibility, with BioMedomics reporting sensitivity and specificity exceeding 99% for its Sickle SCAN diagnostic platform.
  • Regional Leadership: North America leads the Sickle Cell Disease Diagnosis Market with an indicative 35% share, supported by established newborn screening programs, advanced laboratory infrastructure, and specialized hematology services.
  • Competitive Landscape: Fisher Scientific leads the illustrative competitive assessment with a 19% market share, supported by its extensive laboratory distribution network, diagnostic testing portfolio, and established healthcare supply capabilities.
  • Market Segmentation: Can distinguish dominates the Sickle Cell Disease Diagnosis Market with an indicative 68% share, supported by growing demand for accurate hemoglobin differentiation, carrier identification, and reliable diagnostic testing.
  • Recent Development: BioMedomics gained additional diagnostic relevance through an independent February 2026 clinical study evaluating its Sickle SCAN platform, which reported 97.3% overall hemoglobin phenotype identification accuracy, strengthening evidence for rapid point-of-care screening.

Rapid point-of-care hemoglobin testing represents an important trend in the Sickle Cell Disease Diagnosis Market as healthcare providers seek accessible methods for identifying affected individuals. BioMedomics reports sensitivity and specificity exceeding 99% for its Sickle SCAN platform, highlighting the potential of compact immunoassays to support reliable initial assessment. Technologies capable of recognizing hemoglobin A, S, and C offer advantages over basic screening methods that cannot distinguish carrier status from disease. Healthcare professionals increasingly evaluate ease of specimen collection, minimal equipment requirements, and straightforward result interpretation. These characteristics support screening programs in community clinics, maternity facilities, and locations with limited access to centralized diagnostic laboratories.

Expansion of newborn screening and integrated diagnostic referral pathways is also influencing market development. A multicountry African screening initiative reported an overall sickle cell disease detection rate of 1.46% among participating infants, demonstrating the importance of organized screening in high-burden settings. Public health programs increasingly emphasize confirmatory testing, family notification, and early linkage to preventive care. Laboratories are strengthening quality-control procedures and standardizing interpretation of abnormal hemoglobin patterns. 

Sickle Cell Disease Diagnosis Market Dynamics

Driver

"Expanding newborn screening and early disease identification."

Growing recognition of sickle cell disease as a preventable contributor to childhood mortality supports diagnostic testing demand. Sub-Saharan Africa accounts for nearly 80% of the global disease burden, creating substantial opportunities for improved screening access and earlier treatment initiation. Early diagnosis enables timely counseling, vaccination planning, infection prevention, and specialist follow-up. Healthcare authorities increasingly recognize newborn identification as an essential component of effective disease management. Diagnostic manufacturers are consequently prioritizing affordable assays, simplified workflows, and testing systems compatible with regional healthcare infrastructure.

Established screening programs also support consistent demand for laboratory supplies and confirmatory testing. In the United States, newborn screening for sickle cell disease operates across all 50 states, creating structured procedures for identifying infants with abnormal hemoglobin patterns. Diagnostic activity extends beyond initial specimen testing to confirmation, patient education, and additional family assessment. Growing emphasis on coordinated care encourages hospitals and laboratories to maintain reliable diagnostic pathways. Improvements in electronic reporting and quality assurance further strengthen program effectiveness.

Restraint

"Limited diagnostic differentiation and laboratory accessibility constrain adoption."

Inadequate diagnostic infrastructure remains an important restraint in regions carrying substantial sickle cell disease burdens. Cannot distinguish represents an indicative 32% of product demand, reflecting continued use of tests that detect abnormal hemoglobin without reliably differentiating disease from carrier status. Such methods may require additional laboratory confirmation before definitive diagnosis. Limited availability of chromatography equipment, trained personnel, reliable electricity, and specimen transportation complicates testing programs. Inconsistent access can delay clinical assessment and reduce continuity between screening and treatment.

Financial and operational barriers further affect diagnostic expansion. During 2026, healthcare organizations continued evaluating testing costs alongside laboratory maintenance, quality-control materials, training requirements, and referral expenses. Small clinics may depend on basic assays because comprehensive platforms require greater investment. Rapid tests can improve accessibility but still require suitable clinical interpretation and confirmatory pathways. Incomplete documentation and fragmented healthcare records can create additional difficulties in tracking positive screening results and ensuring timely follow-up.

Opportunity

"Accessible rapid diagnostics and screening expansion create growth potential."

Point-of-care testing creates important opportunities for suppliers developing affordable and portable hemoglobin detection technologies. BioMedomics describes a diagnostic turnaround of approximately 5 minutes for Sickle SCAN, illustrating how rapid testing can improve access where centralized laboratories are difficult to reach. Compact assays support screening in community settings and may help healthcare workers identify individuals requiring further evaluation. Manufacturers can differentiate their offerings through dependable analytical performance, easy sample handling, and clear interpretation of hemoglobin variants.

Expansion of screening programs in developing healthcare markets creates additional commercial opportunities. During 2026, international health initiatives emphasized earlier detection and integrated clinical follow-up for inherited blood disorders. Diagnostic providers can support these priorities through regional distribution partnerships, training programs, laboratory quality assurance, and affordable test configurations. The ability to connect rapid screening with confirmatory testing and treatment referral represents an important opportunity for sustainable healthcare improvement.

Challenge

"Accurate interpretation and reliable follow-up remain essential."

Maintaining diagnostic accuracy across different hemoglobin patterns represents an important industry challenge. A clinical evaluation published in 2026 reported 96.8% sensitivity for detecting sickle cell trait using Sickle SCAN, illustrating the importance of evaluating performance for specific clinical purposes. Diagnostic accuracy may vary with sample characteristics, test design, and patient populations. Newborn samples require particular attention because fetal hemoglobin patterns differ from those of older children and adults. Laboratories must use validated procedures and appropriate confirmation before establishing definitive diagnoses.

Connecting screening results with clinical follow-up remains another significant challenge. During 2026, healthcare programs continued emphasizing the importance of timely referral, counseling, and longitudinal care after abnormal test results. Geographic access limitations and inconsistent patient tracking can reduce the benefit of early detection. Successful programs require coordinated laboratory reporting, dependable communication, and trained clinical personnel. Manufacturers and healthcare providers must address these operational requirements alongside improvements in diagnostic technology.

Sickle Cell Disease Diagnosis Market Segmentation

Global Sickle Cell Disease Diagnosis Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Can distinguish: Can distinguish represents an indicative 68% share of the Sickle Cell Disease Diagnosis Market, supported by demand for diagnostic systems capable of identifying different hemoglobin patterns. These tests help differentiate sickle cell disease, carrier status, and selected hemoglobin variants, supporting appropriate clinical interpretation. Multiplex immunoassays, laboratory electrophoresis, and chromatography-based methods contribute to this category. Healthcare providers prioritize dependable results because treatment planning, reproductive counseling, and newborn follow-up depend on accurate classification. Growing diagnostic awareness encourages adoption of differentiated testing within hospitals, specialized laboratories, and community screening programs.

Cannot distinguish: Cannot distinguish accounts for an indicative 32% market share, reflecting continued use of basic screening methods that identify the presence of sickle hemoglobin without differentiating disease from carrier status. These tests are used in selected preliminary screening environments where affordability and straightforward operation are important. Basic solubility approaches can support initial assessment but cannot independently establish a complete hemoglobin diagnosis. Follow-up testing is necessary when differentiation affects clinical decision-making. Their continued relevance reflects unequal access to comprehensive diagnostic equipment across healthcare systems.

By Applications

Newborn: Newborn represents an indicative 63% application share, supported by the clinical importance of identifying sickle cell disease shortly after birth. Early testing enables healthcare professionals to arrange preventive treatment, specialist assessment, and parental counseling before serious complications develop. Established screening programs typically collect blood specimens during the initial period after delivery. Laboratory analysis identifies abnormal hemoglobin patterns, while confirmatory procedures establish the diagnosis. Growing recognition of inherited blood disorders strengthens demand for reliable neonatal screening technologies and coordinated clinical follow-up.

Adult: Adult accounts for an indicative 37% application share, supported by diagnostic requirements involving carrier identification, reproductive planning, and assessment of previously undiagnosed individuals. Adults may undergo testing following family history evaluation, abnormal hematological findings, or clinical symptoms suggesting inherited hemoglobin disorders. Differentiation between carrier status and disease is particularly important for genetic counseling. Laboratory testing also supports evaluation of individuals whose newborn screening records are unavailable. Healthcare professionals select methods according to diagnostic purpose, clinical history, and laboratory accessibility.Point-of-care technologies can provide preliminary results, while confirmatory laboratory methods remain important when clinical classification is required. 

Sickle Cell Disease Diagnosis Market Regional Outlook

Global Sickle Cell Disease Diagnosis Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America leads the Sickle Cell Disease Diagnosis Market with an indicative 35% share, supported by established newborn screening infrastructure and specialized diagnostic laboratory networks. The United States maintains comprehensive screening programs across its states, while Canada provides diagnostic services through provincial healthcare systems. Advanced laboratory technologies support identification of hemoglobin variants and confirmatory testing. Healthcare institutions increasingly emphasize appropriate clinical follow-up, genetic counseling, and structured patient monitoring. Established reimbursement arrangements and diagnostic equipment availability contribute to regional market activity. Suppliers compete through product reliability, laboratory compatibility, distribution capabilities, and technical support. Continued emphasis on accessible screening and appropriate clinical interpretation supports regional demand.

Europe

Europe represents an indicative 24% market share, supported by developed laboratory infrastructure and growing recognition of inherited hemoglobin disorders. The United Kingdom, France, Germany, and other European countries maintain diagnostic capabilities for hemoglobin variant analysis. Population diversity and established healthcare services influence demand for newborn screening and adult testing. Laboratories increasingly prioritize accurate differentiation between carrier status and disease. Clinical genetics services also contribute to diagnostic assessment and counseling. Regulatory compliance, analytical performance, and integration with established clinical pathways remain important technology purchasing considerations.

Asia-Pacific

Asia-Pacific accounts for an indicative 22% share, reflecting increasing diagnostic awareness and expanding healthcare infrastructure. India represents an important market because inherited hemoglobin disorders affect several population groups and geographic communities. Regional demand is supported by screening initiatives, improved laboratory availability, and growing interest in portable diagnostics. China, Australia, and other markets contribute through specialized laboratory services and hematology care. Unequal access to confirmatory equipment creates opportunities for affordable screening technologies. Laboratory confirmation and patient counseling remain essential for effective disease classification. Manufacturers offering affordable products, training support, and dependable distribution may benefit from expanding diagnostic access initiatives.

Middle East and Africa

Middle East and Africa represents an indicative 16% diagnostic market share despite carrying a substantial proportion of the global disease burden. The difference between disease prevalence and estimated commercial market share reflects unequal healthcare spending and diagnostic access. Sub-Saharan Africa has particularly significant unmet screening requirements, while several Middle Eastern countries maintain established hereditary disease testing programs. Demand is influenced by newborn screening initiatives, public health investment, and laboratory infrastructure development. Portable technologies can support screening where conventional equipment remains limited.Opportunities remain substantial for affordable assays and localized distribution. Successful implementation requires trained personnel, reliable supplies, and dependable pathways for confirmatory testing and clinical care.

Rest of the World

Rest of the World accounts for an indicative 3% share, including markets outside the principal regional allocations. Demand reflects hereditary disease screening requirements, improved diagnostic awareness, and gradual expansion of laboratory capacity. Parts of the Caribbean and Latin America have meaningful sickle cell disease burdens, although testing accessibility varies. Healthcare providers increasingly seek methods that support early identification and appropriate differentiation of abnormal hemoglobin patterns. Improving laboratory networks may support continued development of testing services across these markets.

List of Top Sickle Cell Disease Diagnosis Market Companies

  • Fisher Scientific
  • Atlas Medical
  • BioMedomics Inc
  • Arlington Scientific, Inc
  • Silver Lake Research Corporation

Top Two Companies with Highest Market Share

  • Fisher Scientific: Fisher Scientific holds an illustrative 19% share within the competitive assessment, supported by its laboratory supply infrastructure, diagnostic equipment distribution, and established relationships with healthcare institutions. The company supports access to laboratory products used in hematology testing and diagnostic workflows. Its distribution capabilities contribute to procurement efficiency and laboratory operations. The assigned share is an analytical estimate rather than a verified company-specific market measurement.
  • BioMedomics Inc: BioMedomics Inc represents an illustrative 16% market share, reflecting its specialized rapid diagnostic portfolio and Sickle SCAN technology. The platform can identify hemoglobin A, S, and C patterns, supporting differentiation between normal, carrier, and sickle cell disease samples. Its compact testing format is relevant to community screening and decentralized healthcare. The stated share is indicative and has not been independently established through audited competitor sales data.

Investment Analysis and Opportunities

Investment opportunities in the Sickle Cell Disease Diagnosis Market increasingly focus on affordable screening technologies, diagnostic infrastructure, and reliable confirmatory testing. Global health estimates identified approximately 515,000 births affected by sickle cell disease in 2021, illustrating the substantial population requiring early diagnostic services. Healthcare investors and manufacturers are evaluating technologies that simplify specimen processing and reduce dependence on sophisticated laboratory equipment. Portable immunoassays, improved quality-control materials, and integrated reporting systems are particularly relevant to community health programs. Commercial success depends on affordability, regulatory compliance, dependable supply chains, and appropriate clinical validation.

Expansion of organized newborn screening represents another important investment opportunity. During 2026, healthcare initiatives emphasized broader testing access and improved follow-up for affected children. Diagnostic suppliers can support these priorities through training, regional partnerships, and standardized screening kits. Laboratories also require instruments, consumables, technical support, and dependable confirmation procedures. Investment in digital reporting can improve patient tracking and referral coordination. Programs integrating diagnostic services with preventive healthcare may support sustainable demand beyond initial screening activities.

New Product Development

New product development increasingly emphasizes differentiation of hemoglobin variants, simplified test operation, and improved analytical reliability. BioMedomics reports that Sickle SCAN can deliver results within approximately 5 minutes, demonstrating the potential of rapid point-of-care immunoassays. Technologies capable of identifying hemoglobin A, S, and C provide clinically useful information for preliminary classification. Manufacturers are evaluating user-friendly sample collection, stable reagents, and visually interpretable results. Product designs must also address limitations associated with newborn testing and uncommon hemoglobin patterns.

Laboratory-compatible diagnostic innovation remains important alongside portable screening. During 2026, clinical research continued evaluating hemoglobin separation technologies and comparisons with established electrophoresis methods. Manufacturers are focusing on analytical precision, reduced sample requirements, and efficient laboratory workflows. Automated result interpretation may support consistent reporting, although clinical oversight remains necessary. Product development increasingly considers both technological accuracy and suitability for healthcare environments with limited resources.

Five Recent Developments

  • February 2026 – BioMedomics Sickle SCAN Receives Further Clinical Validation: An independent neonatal diagnostic study published on February 26 evaluated BioMedomics Sickle SCAN using 365 newborn samples and reported 97.3% overall hemoglobin phenotype identification accuracy. The findings strengthened clinical evidence supporting point-of-care screening in resource-limited settings. BioMedomics holds an indicative 16% market share in the supplied competitive assessment.
  • Fisher Scientific – Existing Sickle Cell Testing Portfolio: Fisher Scientific continues listing SickleScreen assay kits, sickle cell solubility tests, and hematology control materials for clinical laboratory applications. A specific product launch or portfolio expansion dated 2026 could not be verified.
  • Atlas Medical – Established Hemoglobin Screening Technology: Atlas Medical offers sickle cell testing kits supporting hemoglobin S detection and differentiation procedures. Its existing product documentation describes diagnostic methods, but no distinct 2026 company development could be confirmed.
  • Arlington Scientific – Continued Diagnostic Test Availability: Arlington Scientific offers its ASI Sickle Cell Test for qualitative hemoglobin S detection, with manufacturer-reported sensitivity and specificity exceeding 99%. A new product announcement or regulatory milestone in 2026 could not be established.
  • Silver Lake Research Corporation – Affordable Diagnostic Access Initiative: Silver Lake Research supports access to HemoTypeSC through its agreement with the Clinton Health Access Initiative, designed to improve affordable sickle cell screening in underserved communities. The agreement was announced in May 2025, and no separate qualifying 2026 announcement was verified.

Report Coverage

The Sickle Cell Disease Diagnosis Market report examines industry conditions across the 2026–2035 forecast period, including screening demand, diagnostic innovation, clinical testing requirements, and healthcare accessibility. Product segmentation includes Can distinguish and Cannot distinguish, while application analysis covers Newborn and Adult testing. The assessment evaluates rapid immunoassays, laboratory hemoglobin analysis, confirmatory diagnostic procedures, and technology implementation requirements. Competitive coverage addresses the five supplied companies and their positions within the diagnostic supply landscape.

Regional analysis covers North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of the World. The report evaluates diagnostic infrastructure, screening initiatives, technology accessibility, and investment opportunities across these markets. It also considers product development, public health initiatives, and operational challenges affecting diagnostic expansion. Percentage-based segment and competitor allocations are indicative analytical estimates requiring independent validation before publication as measured market shares. The development review includes documented diagnostic research and public health activities; separate company-specific product announcements were not established for every named manufacturer during the review period.

Sickle Cell Disease Diagnosis Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 70.91 Million in 2026

Market Size Value By

USD 111.13 Million by 2035

Growth Rate

CAGR of 5.12% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Can distinguish
  • Cannot distinguish

By Application :

  • Newborn
  • Adult

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Sickle Cell Disease Diagnosis Market is expected to reach USD 111.13 Million by 2035.

The Sickle Cell Disease Diagnosis Market is expected to exhibit a CAGR of 5.12% by 2035.

Fisher Scientific, Atlas Medical, BioMedomics Inc, Arlington Scientific, Inc, Silver Lake Research Corporation

In 2026, the Sickle Cell Disease Diagnosis Market value will reach at USD 70.91 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified